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Abstract Aarskog^Scott Syndrome (AAS) is an X-linked
disorder characterised by short stature and multiple facial, limb
and genital abnormalities. A gene, FGD1, altered in a patient
with AAS phenotype, has been identified and found to encode a
protein with homology to Rho/Rac guanine nucleotide exchange
factors (Rho/Rac GEF). However, since this original report on
identification of a mutated FGD1 gene in an AAS patient, no
additional mutations in the FGD1 gene have been described. We
analysed 13 independent patients with clinical diagnosis of AAS.
One patient presented a mutation that results in a nucleotide
change in exon 10 of the FGD1 gene (G2559sA) substituting a
Gln for Arg in position 610. The mutation was found to segregate
with the AAS phenotype in affected males and carrier females in
the family of this patient. Interestingly, Arg-610 is located within
one of the two pleckstrin homology (PH) domains of the FGD1
gene and it corresponds to a highly conserved residue which has
been involved in InsP binding in PH domains of other proteins.
The same residue is often mutated in the Bruton’s tyrosine kinase
(Btk) gene in patients with an X-linked agammaglobulinemia.
The Arg610Gln mutation represents the first case of a mutation
in the PH domain of the FGD1 gene and additional evidence that
mutations in PH domains can be associated to human
diseases. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Aarskog^Scott Syndrome (AAS), also referred as faciogen-
ital syndrome or faciodigitogenital syndrome (MIM #
305400), is an X-linked disorder characterised by multiple
limb and genital abnormalities with short stature, ocular hy-
pertelorism, downslanting palpebral ¢ssures, anteverted nos-
trils, shawl scrotum, broad and short hands, hyperextensibility
of the proximal interphalangeal joints and, occasionally, slight
mental retardation [1^3]. Establishing the carrier status in
females is di⁄cult since they are largely asymptomatic,
although they can occasionally present a partial expression
of the syndrome with short stature, small hands and feet
and some facial features. In 1993, a locus for the AAS was
mapped to the Xp11.12 region by studies on a family in which
a balanced X-autosome translocation segregated with Aar-
skog Syndrome [4] and a gene, termed FGD1, was identi¢ed
by Pasteris et al. [5]. The human FGD1 gene is subdivided
into 18 exons spanning over 51 kb of genomic DNA from
which a 4.4 kb mRNA is transcribed which codes for a pro-
tein of 961 amino acids [6]. The predicted FGD1 protein
contains domains normally involved in signal transduction
pathways, including two pleckstrin homology (PH) domains,
a putative Src homology 3 (SH3)-binding region and a DBL
homology (DH) domain [5]. The presence of PH and DH
domains suggests that FGD1 may act as a guanine nucleotide
exchange factor (GEF) for members of the Rho/Rac family of
small GTP-binding proteins, binding speci¢cally to the Rho
GTPase cdc42 and stimulating the GDP^GTP exchange of the
isoprenylated form of cdc42 [6,7]. In their initial report, Pas-
teris et al. [5] demonstrated that an insertion of a guanine
residue after nucleotide 2122 resulted in a frameshift predicted
to cause premature translation termination at codon 469. De-
spite the relative frequency of the clinically diagnosed AAS
patients [3,8] and the availability of a DNA analysis, however,
additional mutations in the FGD1 gene have not been further
reported, leading to the suspicion that the syndrome could
encompass a group of genetically heterogeneous disorders re-
sulting from mutations of di¡erent genes.
In the course of a study on AAS, DNA samples from 13
unrelated patients were screened for mutations in the FGD1
gene. In one of these patients, a point mutation (G2559A) was
identi¢ed in exon 10, changing a Gln for Arg in position 610.
Extension of the molecular characterisation to the entire fam-
ily revealed that the mutation was associated to the typical
AAS phenotype in all the a¡ected members.
2. Materials and methods
2.1. Patients
We included in this study 13 independent patients who were clin-
ically examined and ¢tted a clinical diagnosis of AAS in accord with
the primary and secondary diagnostic criteria for AAS as derived by
Teebi et al. [9]. The family, in which the Arg610sGln mutation was
identi¢ed, was investigated following genetic counselling for a clinical
diagnosis of the proband (IV9), examined when he was 2 years old.
On physical examination, he ¢tted the clinical description of classical
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AAS as he was a subject of short stature (87 cm, 32 S.D.) and normal
intelligence with round faces, prominent foreheads with widow’s peak,
hypertelorism, antimongoloid slant of palpebral fessures, bilateral
ptosis, hypoplasia of the midface, short and broad nose with ante-
verted nostrils and long broad philtrum, small hands and feet. The
typical genital appearance reported in AAS (shawl scrotum) was not
evident, while bilateral criptorchidism had been surgically corrected.
Within the family the trait segregated with a typical X-linked pattern
of inheritance (Fig. 1) as there were six males in four generations, of
which three examined, which presented a phenotype compatible with
AAS. Some of the females (including the mother of patient IV9)
presented a milder expression of the clinical manifestations. Molecular
analysis of the FGD1 gene started from IV9 and additional members
were recruited subsequently when molecular genetic testing was of-
fered to all the subjects at risk. Overall, 13 members of the family
were clinically evaluated and their DNA collected. The male subjects
II1 and IV10 were of short stature and showed features similar to
those of patient IV9. Partial expression of the syndrome seemed to be
present in four examined females (III1, III4, IV8 and IV11) who had
short stature, small hands and feet, short neck, and a round face with
widow’s peak. Other females of the family (III2, III3, and IV7)
presented similar facial and digital features without short stature
(Table 1).
2.2. Mutational analysis
Genomic DNA was extracted from blood leukocytes using a stan-
dard protocol [10]. Exons 1^18 of the FGD1 gene were ampli¢ed by
PCR to give products in the size range 150 to 250 bp suitable for the
subsequent single strand conformational polymorphism (SSCP) anal-
ysis. Primer sequences were designed to span the intron/exon bound-
ary regions of the published sequence of the gene (GeneBank se-
quence: U11690) and in part suggested by Dr. Schwartz CE
(personal communication). PCR reactions were performed in 25 Wl
containing 100 ng of genomic DNA, 1UPCR bu¡er (Perkin Elmer),
0.5 pmol of each primers, 180 WM of each dNTP and 1 U of Taq
DNA polymerase (Perkin Elmer). Ampli¢ed samples were diluted 1:1
in formamide bu¡er (95% formamide, 10 mM NaOH, 0.025% bro-
mophenol blue and 0.025% xylene cyanol), denatured at 95‡C for
5 min and cooled on ice. 4^8 Wl of PCR products were loaded on
non-denaturating polyacrylamide gel containing 6% acrylamide pre-
pared with a 99:1 ratio between acrylamide and bis-acrylamide. Gels
were run in a cold room for 1^4 h at 30 W. DNA bands were visual-
ised by silver staining. PCR products that revealed an aberrant con-
former were ¢rst recon¢rmed by an independent PCR and then puri-
¢ed using Qiagen puri¢cation columns according to manufacturing
instructions and both strands were sequenced using the Sequenase
2.0 kit (USB).
3. Results
Based on the known structure of the FGD1 gene, DNA
primers were designed to cover all 18 exons of the FGD1
gene. Single strand conformation polymorphism (SSCP) was
performed on all 18 exons of the FGD1 gene in 13 independ-
ent patients who ¢tted a clinical diagnosis of AAS according
to the primary and secondary diagnostic criteria for AAS as
derived by Teebi et al. [9]. In one patient we found a base
change (GsC) in position +24 in intron 12. Since mutations
at this position cannot cause splicing defects and given that it
was found in eight of 56 (14.3%) normal chromosomes, we
consider this base substitution as a common polymorphism.
In a second patient, the subject IV9 of the family in Fig. 1,
we found a mutation in exon 10 of the FGD1 gene
(G2559sA) which substitutes a Gln for Arg in position
610. This mutation was absent in 106 normal X chromo-
somes. SSCP and sequence analysis of exon 10 was extended
to the family of this patient, allowing the assessment of co-
segregation of the mutated allele with the AAS phenotype in
other a¡ected males and in carrier females.
The pedigree of this family (Fig. 1) showed an X-linked
pattern of inheritance with six a¡ected males in four genera-
tions (three examined) and some females with a milder expres-
sion of the trait. Among the examined members, the male
subjects II1 (66 years old) and IV10 (19 years old) were found
to carry the G2559sA mutation. They were of short stature
(157 cm and 156 cm respectively) and showed similar facial,
limb and genital features (Table 1). In addition, by medical
records and photographs obtained by family members who
underwent genetic counselling, strikingly similar features
were detected in three other subjects of the family (II4, II7,
III5) who were not available for further investigation since
individual III5 had died, and II4 and II7 could not be traced.
Fig. 1. A: Pedigree of the AAS family carrying the Arg610Gln mutation. Black symbols denote a¡ected individuals; white symbols refer to un-
a¡ected individuals; central dot symbols indicate carrier females. Clinical examination and molecular analysis were carried out for the individu-
als referred to by asterisks. B: Direct sequencing of the exon 10 in di¡erent subjects of the family.
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Partial expression of the AAS phenotype was observed in four
examined females (III1, III4, IV8 and IV11) who had short
stature, small hands and feet, short neck, and a round face
with widow’s peak. Other females of the family (III2, III3,
and IV7) presented similar facial and digital features without
short stature (Table 1). All these seven females were found to
carry the mutated allele in the heterozygote state (Fig. 1).
Subjects IV5, IV6 and IV12, essentially free of clinical mani-
festations, were found to carry the normal allele.
4. Discussion
Overlapping phenotypes resulting from genetic heterogene-
ity represent a great limitation toward the identi¢cation of
mutations causing human disease. Faciogenital or Aarskog^
Scott Syndrome is frequently diagnosed after clinical evalua-
tion of X-linked traits with facial dysmorphic features and
short stature. Nevertheless, after the ¢rst reported mutation
in the FGD1 gene in an AAS family by Pasteris et al. in 1994
[5], there have been no additional reports of mutations in the
FGD1 gene, contravening the expectation of a univocal geno-
type^phenotype correlation. This has led to the suspicion
that the AAS syndrome may encompass a group of genetically
heterogeneous disorders, resulting from mutations of di¡erent
genes. Analysis of all exons and of their £anking consensus
splicing sites of the FGD1 gene was carried out in 13 inde-
pendent patients ¢tting the clinical criteria for the diagnosis of
AAS. In one of these patients we identi¢ed a base change
(GsC) at position +24 in intron 12. Since mutations at
this residue cannot cause splicing defects, and since the muta-
tion was found in eight of 56 (14.3%) normal X chromosomes,
we consider this base substitution as a common polymor-
phism.
A second patient was found to carry a mutation in exon 10
of the FGD1 gene (G2559sA) which substitutes a Gln for
Arg in position 610. When the analysis of the FGD1 gene was
extended to members of the family of this patient, the mutated
allele was found to segregate with the AAS phenotype in
a¡ected males and carrier females. Overall, in this family we
found three a¡ected males and seven carrier females out of 13
members examined. A¡ected males had the clinical features
typical of the AAS and are phenotypically similar to previ-
ously reported a¡ected subjects, but shawl scrotum, reported
as one of the typical signs was barely detectable in our male
patients. Furthermore, the phenotype of carrier females was
very variable, ranging from near normal to clear facial and
digital abnormalities. In particular, we found that short stat-
ure is not a constant feature in carrier females, as it is present
in four out of seven carrier females, while it is present in all
a¡ected males of the family. This seems to be a distinguishing
character between carrier females and a¡ected males, as short
stature is considered a primary criterion for diagnosis. Other
features (digital anomalies, widow’s peak, and shape of the
mouth) are completely ful¢lled and therefore seem more spe-
ci¢c and thus critical for the identi¢cation of the carrier fe-
male at the clinical level at least in this family.
The Arg-610 to Gln mutation in the FGD1 gene is the
second mutation found in patients with AAS following iden-
ti¢cation of the FGD1 gene. The mutation alters the coding
sequence of the FGD1 PH domain (aa 590^689), a 100-resi-
Table 1
Summary and comparison of the clinical ¢ndings for the ASS subjects of the reported family
Primary criteria Females Males
III1 III2 III3 III4 IV7 IV8 IV11 II1 IV9 IV10
Hypertelorism 3 + + 3 + 3 3 + + +
Short nose/Ant. nares + 3 3 3 3 3 3 + + +
Crese below lower lip + 3 3 + 3 + 3 + + +
Short broad hands + + + + 3 + + + + +
Interdigital webbing + + + + + + + + + +
Shawl scrotum +/3 +/3 +/3
Short ¢fth ¢nger/Clinod. + + + + + + + + + +
Camptodactily 3 3 + 3 3 3 3 + 3 3
Short stature + 3 3 + 3 + + + + +
Secondary criteria
Widow’s peak + + + + 3 + + + + +
Ptosis 3 + 3 3 3 3 3 + + +
Downward slant palp + + 3 3 3 3 3 + + +
Abnormal auricles 3 3 3 3 3 + 3 3 + 3
Joint hyperextension 3 3 3 3 3 3 3 3 + +
Broad feet 3 3 3 3 3 3 3 3 + 3
Cryptorchidism/ingui. umbilical hernia + + +
The ASS diagnostic criteria (primary and secondary criteria) were derived from Teebi et al. [9].
Fig. 2. Multiple sequence alignment of the L1^L2 region of PH do-
mains involved in phosphoinositide binding. The FGD1 sequence
shown here corresponds to residues 593^614 of human FGD1 (Gen-
Bank accession code GI4758358). Residue numbering refers to posi-
tions within each speci¢c secondary structure elements, L1-strand,
L1^L2 loop, and L2-strand. Two conserved hydrophobic residues at
positions 5 and 6 of L1 and L2 respectively are important for the
structural stability of the domain (dark grey columns with white
type). Positions implicated in phosphoinositide binding are greyed.
The Arg610Gln mutation a¡ects an arginine residue (position 4 of
L2) that is conserved in high-a⁄nity phosphoinositide-binding PH
domains such as the ones shown in this alignment.
FEBS 23975 28-7-00
A. Orrico et al./FEBS Letters 478 (2000) 216^220218
due module that has been identi¢ed in over one hundred
protein sequences [11,12]. Although there may be some func-
tional variability within the PH domain family, it is now
widely accepted that the majority of the members of the fam-
ily are involved in binding of the phosphorylated head of
inositol phospholipids (inositol phosphate, InsP) [12,13].
Phosphoinositides play a central role in a number of cellu-
lar processes, ranging from the intracellular transduction of
signals originating at the plasma membrane, to the organisa-
tion of the actin cytoskeleton, to the prevention of apoptosis,
to the regulation of vesicular endocytosis [13,14]. The absolute
relevance of phosphoinositide binding by PH domain for
proper cellular metabolism is demonstrated by the existence
of disease-causing mutations a¡ecting PH domain^lipid inter-
action in humans. In fact, critical missense mutations within
the PH domain of the Btk gene result in a severe human
immunode¢ciency known as X-linked agammaglobulinemia
(XLA) [15].
Early structural analyses revealed that the PH domain folds
into a seven-stranded L-barrell [16]. Successive structural stud-
ies of the PLCD PH domain complexed with inositol (1,4,5)
triphosphate (Ins(1,4,5)P3), and of the Btk PH domain in
complex with Ins(1,3,4,5)P4, revealed that the region located
near the N-terminal end of the domain, comprising L-strands
L1 and L2, and the loop connecting them (L1^L2 loop), is
critically involved in substrate binding. The combination of
structural information with data gathered from studies mea-
suring the binding of several PH domains to di¡erentially
phosphorylated inositols, has allowed a preliminary de¢nition
of the minimal sequence requirements for selective InsP bind-
ing [16]. These studies seem to conclude that despite the direct
involvement of other regions of the domain in substrate bind-
ing, most and probably all sequence information necessary to
encode selective phosphoinositide recognition is contained
within the L1^L2 region of the domain. A sequence alignment
of this region is shown in Fig. 2. The reliability of the align-
ment is guaranteed by the presence of two very well conserved
hydrophobic residues in positions £anking the L1^L2 region,
which are essential determinants of the structural stability of
the domain (at position +5 of the L1-strand and position +6
of the L2-strand). Residues implicated in InsP binding by
other PH domains are conserved in the FGD1 domain,
strongly suggesting that this domain is also involved in InsP
binding. In particular, the alignment reveals a very strong
similarity between the FGD1 and ARK PH domain. The
latter has been shown to be involved in binding PtdIns-4,5-
P2 and PtdIns-3,4,5-P3 [17]. The FGD1 mutation falls at po-
sition +4 from the start of the L2-strand. Within phosphoino-
sitide-binding PH domains, the +4 position is occupied by an
Arg residue, which the aforementioned crystal structures re-
vealed to be critically involved in InsP binding [18^20]. In
fact, mutations a¡ecting the same position in the Btk PH
domain (Arg28 in the Btk sequence) result in X-linked agam-
maglobulinemia [15,21^23]. Thus, it appears that the deleteri-
ous e¡ect of the Arg610Gln mutation described in this study
may result from the inability of the mutated PH domain to
interact with a lipid functional modulator. Based on the func-
tions of other PH domain containing proteins [24] we spec-
ulate that the mutation may hamper the localisation of FGD1
to speci¢c cellular compartments, thus altering the GDP^GTP
exchange function of the associated DH- and SH3-binding
motifs.
Another example of disease with mutations a¡ecting the
function of a PH domain has been suggested to be represented
by the X-linked Wiskott^Aldrich Syndrome (WAS) and its
allelic variant X-linked thrombocytopenia (XLT) [25^30].
Nevertheless, the presence of a genuine PH domain in the
WAS protein has been more recently questioned as the
WAS protein sequence aligns very poorly with available mul-
tiple sequence alignments of bona ¢de PH domains. On the
other hand, this sequence can be productively aligned to the
so-called Ena-Vasp homology 1 (EVH1) domain [31]. Inter-
estingly, the determination of the crystal structure of the
EVH1 domain revealed a three-dimensional fold similar to
that of the PH domain [32,33]. Despite structural similarity,
however, the function of the EVH1 is distinct from that of the
PH domain, and consists in polyproline type II (PPII) helix
recognition. Indeed, several domain families have been de-
scribed that share the PH fold while displaying distinct func-
tional properties [12]. It is important to note that the align-
ment of the WAS protein sequence to the PH domain
proposed [29] was largely o¡set with respect to the PH-like
fold of the EVH1 domain [33], and thus did not re£ect the
proper alignment of very divergent sequences sharing a com-
mon fold. Altogether these observations de¢nitively establish
that the WAS protein does not contain a PH domain but
rather an EVH1 domain.
In conclusion, we have found a novel mutation in a family
with the classical manifestation of the AAS, allowing us to
make diagnoses in a¡ected patients and to detect the carrier
females leading to better genetic counselling with respect to
future risks of recurrence in the family. The clinical phenotype
observed in this family may help to elaborate a more speci¢c
de¢nition of the genotype^phenotype correlation in Aarskog^
Scott Syndrome, especially with regard to phenotype of the
carrier females. Furthermore, the present study is the ¢rst to
demonstrate a causative mutation at a sensitive site of the PH
domain of FGD1 protein in AAS, adding this disorder to the
previously reported human disease XLA in which this domain
has been found to be involved. Detection of a novel mutation
in the FGD1 gene con¢rms the pathogenetic role of this gene
in AAS, although the low frequency of mutations so far de-
tected in AAS patients still leaves open the possibility that
other genes may be involved.
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